Kim Stickland
About Kim Stickland
Kim Stickland serves as the Vice President of Preclinical Development at Fulcrum Therapeutics, a position he has held since 2020. He has extensive experience in pharmacotoxicology, having previously worked at Isis Pharmaceuticals, Biogen, and Bristol-Myers Squibb.
Current Role at Fulcrum Therapeutics
Kim Stickland serves as the Vice President of Preclinical Development at Fulcrum Therapeutics. She has held this position since 2020, contributing to the company's focus on advancing innovative therapies. In her role, she oversees preclinical research and development initiatives, ensuring the scientific rigor and safety of potential drug candidates.
Previous Experience in Pharmaceutical Industry
Before joining Fulcrum Therapeutics, Kim Stickland accumulated extensive experience in the pharmaceutical industry. She worked at Isis Pharmaceuticals as Assistant Director of Toxicology from 2002 to 2005. Following that, she held the position of Senior Scientist in Pharmacotoxicology at Biogen from 2005 to 2008. Additionally, she served as Principal Scientist for Preclinical Safety Assessment at Bristol-Myers Squibb for a brief period in 2001 and continued at Biogen as Principal Research Scientist in Preclinical Safety from 2008 to 2012.
Educational Background
Kim Stickland earned her Bachelor of Science degree from the University of Michigan, where she studied from 1988 to 1992. She then pursued advanced studies at the University of Arizona, obtaining her Doctor of Philosophy degree between 1992 and 1997. Her educational background provides a strong foundation for her career in preclinical development and toxicology.